Fish oil infusions tested to tame transplant complication

NCT ID NCT07162688

ENROLLING_BY_INVITATION Disease control Sponsor: Fujian Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether daily intravenous omega-3 fatty acids (fish oil) can reduce the risk and severity of acute graft-versus-host disease (aGVHD) in 30 adults receiving a stem cell transplant. Participants get omega-3 infusions from before transplant until about 35 days after. The main goal is to see if fewer people develop aGVHD within 100 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Omega-3 fatty acids (fish oil) given intravenously
What this could lead to: If it works, this could offer a simple, safe way to lower the risk of a serious complication after stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply widely. Omega-3 may not reduce GVHD enough to change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VERSUS HOST DISEASE (GVHD)

Contacts and locations

Locations

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, 353000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.